2023 Biomarkers of Aging Symposium

Dr. Barzilai is a Chaired Professor of Medicine and Genetics as well as the Director of The Einstein Institute for Aging Research, the largest center in the world to study the Biology of Aging. He leads the TAME (Targeting/Taming Aging with Metformin) multi-central study to prove the concept that multi-morbidities of aging can be delayed in humans and to change the FDA indications to allow for next generation interventions.

Dr. Belsky's work focuses on reducing social inequalities in aging outcomes in the US and beyond. His research seeks to understand how genes and environments combine to shape health across the life course. His aim is to identify targets for policy and clinical interventions to promote positive development in early life and extend healthspan.

Dr. Chen is the Chief Science Officer at FOXO Technologies, specializing in epigenetic technology for assessing human health and aging. He combines his expertise in epidemiology, bioinformatics, and machine learning to discover and validate biomarkers, publishing extensively on aging rates, genetic analysis, and epigenetic clock studies.

Dr. Cohen, an Associate Professor at Columbia University, specializes in elucidating integrative biological processes and identifying reliable biomarkers of aging, health, and system integrity. Through the analysis of epidemiological data, his research contributes to a deeper understanding of health, aging, and longevity at multiple levels.

Dr. Fleming, the founder of Kinexum and a prominent figure in endocrinology, coined the term Metabesity to encompass the metabolic commonalities among cancer, chronic diseases, and aging. With notable achievements at the FDA and extensive involvement in biomarker initiatives and regulatory discussions, he is dedicated to advancing healthspan products and promoting healthy aging through conferences like the Targeting Healthy Longevity Conference.

Dr. Ferrucci, the Scientific Director of the National Institute on Aging (NIA), conducts research on the pathways of physical and cognitive decline in older individuals, with a focus on inflammation, oxidative stress, and molecular damage. His influential work has led to notable progress in preventing and treating age-related diseases, such as cardiovascular disease, cancer, type 2 diabetes, and dementia.

Dr. Fortney is developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. Her company, BioAge, uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent these diseases in entirely new ways.

Dr. Furman, an academic and entrepreneur, specializes in advanced statistics, AI, and machine learning for translational medicine. As the Director of the Stanford 1,000 Immunomes Project and an Associate Professor at the Buck Institute for Research on Aging, his research explores the immune system's involvement in aging and age-related diseases, with a particular focus on biomarkers of aging.

Dr. Gladyshev, a renowned Professor of Medicine at Harvard Medical School and Director of the Center for Redox Medicine at Brigham and Women's, researches aging, lifespan control, and rejuvenation. His focus is on biomarkers of longevity and biological age, such as aging clocks, epigenetic signatures, and the human selenoproteome, revealing insights into aging mechanisms and the dynamic nature of biological aging under varying stress conditions.

Dr. Horvath, a renowned biogerontologist at Altos Labs, specializes in epigenetic biomarkers of aging. His pioneering work includes creating the first saliva epigenetic clock, the pan-tissue Horvath clock, and a universal clock for mammals. With numerous accolades and recognition, he is consistently ranked among the world's most influential scientific researchers.

Dr. Justice's research training spans various disciplines, species, and intervention strategies. Her current research includes the both the clinical trial Targeting Aging with MEtformin (TAME), which is designed to facilitate regulatory approval for metformin in order to slow biological aging, as well as investigating the therapeutic potential of targeting the biologic aging hallmark of cellular senescence in humans.

Dr. Maier focuses on sarcopenia and cellular senescence and their influence on age-related diseases. She serves as a Professor of Gerontology at VU University Amsterdam, The Netherlands, a President of the Australian and New Zealand Society for Sarcopenia and Frailty Research and as an Honorary Professor of Medicine and Aged Care at the University of Melbourne, Australia. She is also an Associate Editor of numerous international journals, such as Frontiers, the Gerontological Society of America, and is on the Editorial Board of ICT&Health.

Dr. Joan Mannick is the Chief Executive Officer of Tornado Therapeutics and develops safer and more effective mTOR inhibitors to treat or prevent disease. Dr. Mannick has extensive academic (Harvard Medical School, University of Massachusetts Medical School) and industry expertise (Novartis, Genzyme, resTORbio, Life Biosciences) in multiple therapeutic areas including aging biology.

Dr. Moqri, a joint Research Fellow at Harvard University’s Gladyshev Lab and Stanford University’s Snyder Lab, specializes in researching epigenetic and multi-omics biomarkers of aging. Additionally, he plays a key role in leading the Executive Committee of the Biomarkers of Aging Consortium, dedicated to establishing robust biomarkers for longevity interventions.

Dr. Schilling, a Professor at the Buck Institute for Research on Aging and Director of the Mass Spectrometry Core, specializes in biomarkers of aging through proteome analysis. Her research examines protein modifications and their relevance to aging and age-related diseases, employing advanced analytical technologies to gain insights into fundamental aging biology and translational research.

Dr. Sebastiano, an Associate Professor at Stanford University, pioneers cellular reprogramming to reverse aging in human cells and tissues. His research explores leveraging reproduction and embryonic development principles for anti-aging technologies, while leading research at Turn Biotechnologies for age-related disease therapies through transient cell reprogramming.

Dr. Snyder, the Stanford B. Ascherman Professor and Chair of Genetics at Stanford University, is a renowned leader in functional genomics and proteomics. His lab pioneers integrative personal omics profiling (iPOP) using cutting-edge technologies to assess disease risk and monitor personalized medicine. Additionally, Dr. Snyder has founded multiple companies, authored a book on genomics and personalized medicine, and serves on several company boards.

The Verdin Lab at the Buck Institute studies the relationship between aging and the immune system as well as how immune aging is regulated by nutrition. His lab has demonstrated how changes in the relative abundance of key cellular metabolites such as NAD+, acetylcoenzyme A, and the ketone body beta-hydroxybutyrate fluctuate under different nutritional conditions, including obesity, calorie restriction, fasting, time-restricted feeding, ketogenic diet, and how this influences immune responses. He is working on key enzymes regulated by these metabolites, which include sirtuins (NAD+), histone acetyltransferases (acetylcoenzyme A), and histone deacetylases (HDACs).

Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine, leads the company in pioneering next-generation generative AI technologies for drug discovery and biomarker development. With substantial funding, global expansion, and numerous partnerships, Insilico has made significant progress, advancing 11 preclinical candidates and entering human clinical trials with AI-discovered targets and designed molecules.